Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE Plus GEMCIS in Locally Advanced Unresectable/Metastatic cHCC-CCA
NCT06855225Phase 2Not yet recruiting
- Start
- Nov 2026
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab and durvalumab in Combined hepatocellular-cholangiocarcinoma (cHCC-CC). Primary endpoint: Confirmed objective response rate at 24 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tremelimumabdurvalumab
03
Conditions
Combined hepatocellular-cholangiocarcinoma (cHCC-CC)
Beyond the preview
Go deeper on NCT06855225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855225.